Risteys · AB1_ASCARIASIS

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — B77 Hospital discharge: ICD-9 — 1270 Hospital discharge: ICD-8 — 1270 Cause of death: ICD-10 — B77 Cause of death: ICD-9 — 1270 Cause of death: ICD-8 — 1270 2 out of 7 registries used, show all original rules.	20
4. Check minimum number of events None	20
5. Include endpoints None	20
6. Filter based on genotype QC (FinnGen only)	20

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	327	195	126
Only index persons	259	158	101
Unadjusted period prevalence (%)
Whole population	0.00	0.01	0.00
Only index persons	0.01	0.01	0.00
Median age at first event (years)
Whole population	16.46	17.00	14.11
Only index persons	12.31	11.96	12.87

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	20	16	-
Unadjusted period prevalence (%)	0.00	0.01	-
Median age at first event (years)	14.34	11.97	-

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3017143) Hepatitis C virus Ab [Presence] in Serum

3.12

1.43

1.5

1.1

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

2.65

1.31

1.6

1.7

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.85

1.30

2.5

3.2

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

0.00

1.30

0.0

1.3

—

8.8

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

2.47

1.08

2.3

2.1

nmol/l

63.7

76.6

1.58

(3026008) Bacteria identified in Urine by Culture

2.35

1.02

2.8

—

(3013512) EKG study

2.29

0.85

3.3

3.8

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

2.11

0.81

6.9

3.8

mmol/l

7.2

6.2

0.47

(3026782) Osmolality of Urine

2.43

0.81

1.8

2.6

mosm/kgh2o

403.2

520.8

—

(36304419) Bacteria [Presence] in Urine

2.02

0.79

2.3

2.9

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.89

0.71

4.1

2.9

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

2.00

0.70

14.9

4.9

mmol/l

1.2

—

(1761868) Lipid panel - Serum or Plasma

1.82

0.67

3.6

2.5

—

(3044640) Blood type and Crossmatch panel - Blood

1.85

0.57

2.4

2.8

—

(3019198) Lymphocytes [#/volume] in Blood

0.58

0.46

9.2

5.3

e9/l

2.0

1.9

—

(4035726)

0.00

0.43

0.0

1.2

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.57

0.43

4.2

3.9

—

(3000492) Spirometry study

0.00

0.42

0.0

1.4

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.56

0.40

2.7

1.9

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.47

0.38

1.3

—

(3002030) Lymphocytes/100 leukocytes in Blood

0.63

0.32

10.7

5.6

28.4

29.1

—

(3001604) Monocytes [#/volume] in Blood

0.64

0.32

9.2

5.3

e9/l

0.6

—

(3019069) Monocytes/100 leukocytes in Blood

0.67

0.32

10.7

6.0

8.2

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

0.68

0.31

11.3

7.8

e9/l

3.5

4.4

—

(3026493) Urate [Moles/volume] in Serum or Plasma

1.37

0.25

2.6

2.5

umol/l

336.0

314.2

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.22

0.0

1.4

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

0.00

0.22

0.0

1.3

—

(1002224) Polysomnography panel

0.00

0.22

0.0

1.0

—

(3003694) ABO and Rh group [Type] in Blood

1.29

0.21

1.7

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

0.66

0.21

2.0

3.7

—

(3022096) Basophils/100 leukocytes in Blood

0.69

0.20

10.7

5.4

1.0

0.6

—

(3018010) Neutrophils/100 leukocytes in Blood

0.69

0.20

9.7

5.8

53.1

56.9

—

(3006504) Eosinophils/100 leukocytes in Blood

0.69

0.20

10.2

5.7

3.9

2.4

—

(3015736) pH of Urine

1.24

0.20

2.6

3.7

—

(3013115) Eosinophils [#/volume] in Blood

0.73

0.20

8.4

5.4

e9/l

0.2

—

(3037467) Urinalysis macro (dipstick) panel - Urine

116

1.34

0.20

6.6

4.2

—

(3015377) Calcium [Moles/volume] in Serum or Plasma

1.12

0.10

3.4

2.1

mmol/l

2.4

—

(42870588) Differential panel, method unspecified - Blood

1.19

0.10

8.3

4.7

—

(40768804) Tissue Pathology biopsy report

1.13

0.09

2.0

1.6

—

(3006315) Basophils [#/volume] in Blood

0.81

0.09

8.0

5.5

e9/l

0.1

0.0

—

(3021589) Normoblasts [#/volume] in Blood

0.84

0.09

10.9

7.2

e9/l

0.0

—

(3044889) 12 lead EKG panel

112

1.18

0.09

3.5

3.3

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.2

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.3

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.3

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.3

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.3

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

0.00

0.0

4.4

—

129.6

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

0.0

1.6

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

0.00

0.0

3.7

—

24.0

—

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.4

—

0.9

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.3

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.0

1.4

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.0

1.0

—

(3041096) Erythrocytes [Presence] in Urine by Automated

0.95

0.00

2.0

3.2

—

(40768443) Skin Pathology biopsy report

0.00

0.0

1.0

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

1.09

0.00

3.9

4.3

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.0

1.5

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

0.0

1.8

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

1.8

—

14.5

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.3

—

(3020891) Body temperature

0.00

0.0

2.6

—

(3019060) Gas panel - Arterial blood

0.00

0.0

2.0

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

0.0

1.1

—

(3020044) Glucose [Moles/volume] in Cerebral spinal fluid

0.00

0.0

1.1

—

3.6

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.0

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

1.2

—

(3019473) Protein [Mass/volume] in Cerebral spinal fluid

0.00

0.0

1.3

—

376.0

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.4

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

0.00

0.0

4.5

—

0.7

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

0.00

0.0

4.5

—

0.7

—

(3002173) Hemoglobin [Mass/volume] in Arterial blood

0.00

0.0

9.0

—

115.8

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.00

0.0

2.1

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3017446) Testosterone [Moles/volume] in Serum or Plasma

0.00

0.0

1.5

—

15.1

—

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_ASCARIASIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have AB1_ASCARIASIS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: AB1_ASCARIASIS – Ascariasis

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	AB1_ASCARIASIS
CONTROL_EXCLUDE	AB1_HELMINTIASES
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	B77
HD_ICD_9	1270
HD_ICD_8	1270
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	B77
COD_ICD_9	1270
COD_ICD_8	1270
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Ascariasis

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints